These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 195729)

  • 1. Physiologic disposition of cytosine arabinoside and its derivatives in man.
    Kreis W; Woodcock TM; Meyers MB; Carlevarini LA; Krakoff IH
    Cancer Treat Rep; 1977 Jul; 61(4):723-6. PubMed ID: 195729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiological disposition of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine in humans.
    Kreis W; Gordon CS; DeJager R; Krakoff IH
    Cancer Res; 1975 Sep; 35(9):2453-60. PubMed ID: 1149046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.
    Kreis W; Woodcock TM; Gordon CS; Krakoff IH
    Cancer Treat Rep; 1977 Oct; 61(7):1347-53. PubMed ID: 589600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic studies of cyclocytidine and arabinosylcytosine in dogs.
    Ho DH; Carter CJ; Loo TL; Abbott RL; McBride CM
    Drug Metab Dispos; 1975; 3(4):309-13. PubMed ID: 240662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemotherapy of the malignancies from the viewpoint of pharmacology and biochemistry of cytosine arabinoside (ara-C) and its derivatives].
    Nakamura T; Ueda T
    Gan To Kagaku Ryoho; 1982 Aug; 9(8):1339-51. PubMed ID: 6191711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
    Kreis W; Hession C; Soricelli A; Scully K
    Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine and cytosine arabinoside in the treatment of murine brain tumor.
    Basler GA; Shapiro WR
    Cancer Treat Rep; 1976 Jul; 60(7):875-9. PubMed ID: 64295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiological distribution of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine (AAFC) in man.
    Kreis W
    Ann N Y Acad Sci; 1975 Aug; 255():213-5. PubMed ID: 1059356
    [No Abstract]   [Full Text] [Related]  

  • 9. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
    Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
    Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A radioimmunoassay for 1-beta-D-arabinofuranosylcytosine.
    Okabayashi T; Mihara S; Repke DB; Moffatt JG
    Cancer Res; 1977 Feb; 37(2):619-24. PubMed ID: 832282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipophilic arabinofuranosyl cytosine derivatives in liposomes.
    Schwendener R; Schott H
    Methods Enzymol; 2005; 391():58-70. PubMed ID: 15721374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI; Powell W
    Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARA-C analogs.
    Alberto P
    Antibiot Chemother (1971); 1978; 23():88-98. PubMed ID: 348088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution and metabolism of lipsome-encapsulated and free 1-beta-D-arabinofuranosylcytosine (Ara-C) in dog and mouse tissues.
    Ellens H; Rustum Y; Mayhew E; Ledesma E
    J Pharmacol Exp Ther; 1982 Aug; 222(2):324-30. PubMed ID: 7097552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of hydroxyurea and thymidine derivatives on the uptake and metabolism of deoxycytidine and arabinofuranosylcytosine in log phase and contact-inhibited human diploid fibroblasts.
    Snyder RD; Malick NC
    Mol Pharmacol; 1985 Dec; 28(6):574-80. PubMed ID: 4079913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
    Ueda T; Kamiya K; Urasaki Y; Wataya S; Kawai Y; Tsutani H; Sugiyama M; Nakamura T
    Cancer Res; 1994 Jan; 54(1):109-13. PubMed ID: 8261429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of tetrahydrouridine on the phosphorylation of 1-beta-D-arabinofuranosyl-cytosine (ara-C) by enzymes from solid tumors in vitro.
    Furner RL; Mellett LB; Herren TC
    J Pharmacol Exp Ther; 1975 Jul; 194(1):103-10. PubMed ID: 1057009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.
    Riccardi R; Chabner B; Glaubiger DL; Wood J; Poplack DG
    Cancer Res; 1982 May; 42(5):1736-9. PubMed ID: 6896013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of response to 1-beta-D-arabinofuranosyl cytosine and metabolism of drug by tumor.
    Gailani S; Nussbaum A
    J Med; 1976; 7(2):93-102. PubMed ID: 1064685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of 5'-esters of 1-beta-D-arabinofuranosylcytosine.
    Ho DH; Neil GL
    Cancer Res; 1977 Jun; 37(6):1640-3. PubMed ID: 870178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.